Clinical Trials Logo

Esophagus Adenocarcinoma clinical trials

View clinical trials related to Esophagus Adenocarcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT06381583 Completed - Esophageal Cancer Clinical Trials

A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma

EMERALD
Start date: April 15, 2023
Phase:
Study type: Observational

This study aims to develop a highly sensitive, specific, and cost-effective blood assay for the early detection of esophageal adenocarcinoma and its precursor lesions, using advanced machine learning and state-of-the-art biological analyses.

NCT ID: NCT06030180 Recruiting - Barrett Esophagus Clinical Trials

CLUE: CLinical Utility Study of EsoGuard

PR-0410
Start date: February 23, 2023
Phase: N/A
Study type: Interventional

Utilize real-world data from the commercial use of EsoGuard testing on samples collected with EsoCheck (EC/EG) to evaluate the impact of EsoGuard results on health care provider's decision for endoscopy referral. Assess patient compliance with recommendations for upper endoscopy, and relationship of compliance to positive EsoGuard results.

NCT ID: NCT05713838 Recruiting - Clinical trials for Esophagus Adenocarcinoma

Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

Start date: August 28, 2023
Phase: Phase 2
Study type: Interventional

The present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial investigating whether a definite organ preservation therapy consisting of the combination of durvalumab with chemoradiation is an efficient and safe treatment option for early stage, cT1 and cT2N0, esophageal adenocarcinoma with indication for radical surgery.

NCT ID: NCT05591053 Recruiting - Esophageal Cancer Clinical Trials

Utility and Usability of ActivSight™ Laser Speckle Imaging in Visualization of Tissue Perfusion and Blood Flow During Esophageal Surgery in Humans

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

ActivSight™ combines an innovative form factor and proprietary software to deliver precise, objective, real-time visualization of blood flow and tissue perfusion intraoperatively for laparoscope-based surgery. A small adaptor that fits between any existing laparoscope and camera systems and a separate light source placed along any current commercial system will deliver objective real-time tissue perfusion and blood flow information intraoperatively. Primary Objective: To determine the feasibility of ActivSight™ in detecting and displaying tissue perfusion and blood flow in the conduit and foregut anastomoses in esophageal resection/reconstructive surgery. The investigators will compare the precision and accuracy among the naked eye inspection, ICG and LSCI in assessing the vascularity of the conduit.

NCT ID: NCT05476796 Recruiting - Clinical trials for Gastric Adenocarcinoma

Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

LOGICAN
Start date: June 23, 2023
Phase: Phase 2
Study type: Interventional

Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5-fluorouracile (5-FU) in frail patients with advanced, recurrent or metastatic gastric, oesophageal or gastroesophageal junction cancer.

NCT ID: NCT05001360 Withdrawn - Clinical trials for Gastric Adenocarcinoma

Study of FMT Combined With Nivolumab in Gastric Cancer

Start date: October 2021
Phase: N/A
Study type: Interventional

This study is a single-arm, single center study. The purpose of this study is to evaluate the efficacy and safety of FMT capsules XBI-302 combined with Nivolumab in the treatment of anti-PD-1/L1 resistant gastric cancer.

NCT ID: NCT04408105 Active, not recruiting - Clinical trials for Gastroesophageal Reflux Disease

Survey Study on Barrett's Esophagus Screening

SCREEN-BE
Start date: February 19, 2020
Phase:
Study type: Observational

The goal of this study is to optimize Barrett's Esophagus (BE) screening to reduce the incidence, morbidity, and mortality of Esophageal Adenocarcinoma (EAC).

NCT ID: NCT04018872 Recruiting - Clinical trials for Gastroesophageal Junction Adenocarcinoma

Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer

Start date: June 24, 2019
Phase: Phase 2
Study type: Interventional

Esophageal cancer, which has a low 5-year overall survival rate for all stages (<20%) , is increasing in incidence. Previous studies have shown that the Hedgehog (Hh) and AKT signaling pathways are activated in a significant proportion of esophageal cancers. Itraconazole, a widely used anti-fungal medication, has been shown to inhibit various pathways involved in esophageal cancer tumorigenesis including Hh and AKT. In this phase II clinical trial, the investigators aim to evaluate the effect of itraconazole as a neoadjuvant therapy following standard of care chemoradiation in the treatment of locoregional esophageal and gastroesophageal junction carcinomas.

NCT ID: NCT03008980 Completed - Barrett Esophagus Clinical Trials

WATS3D for the Detection of Esophageal Dysplasia

Start date: May 2014
Phase:
Study type: Observational

Patients will be recruited from participating institutions prior to planned routine care EGD with WATS3D brush samples and forceps biopsies. Eligibility will be reviewed and patients who are potentially eligible for the study will be approached regarding the study. If interested, participants will be consented and proceed with routine care EGD. The study coordinator or other research personnel will document information from the routine care endoscopy as part of this research study. Follow-up information collected will include WATS3D cytology and forceps biopsy pathology results from any routine care endoscopy performed during the course of participation in the study, any surgeries received and related to their condition, and any other care received as part of their condition. WATS3D samples will be sent to CDx Diagnostics for analysis.